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ABSTRACT 
 
Obesity and type 2 diabetes (T2D) have strong genetic components. Identification of 
susceptibility genes in both diseases will give better knowledge of their 
pathomechanisms and future therapies. In this thesis, the candidate gene approach was 
used to find genetic variations associated with obesity and T2D in a Swedish 
population, including controls with normal glucose tolerance (NGT), subjects with 
impaired glucose tolerance (IGT), patients with T2D and obese subjects. The candidate 
genes were selected based on previous studies and on their role in biological pathways 
relevant for determination of body composition and glucose homeostasis.  
Receptor protein tyrosine phosphatase sigma (RPTPσ) (paper I) has a function in 
cellular receptor signaling and is highly expressed in insulin target tissues. We have 
previously shown that RPTPσ is over-expressed in pancreatic islets and liver of 
spontaneously diabetic Goto–Kakizaki (GK) rats. Single nucleotide polymorphisms 
(SNPs) in the RPTPσ gene were genotyped in NGT subjects, IGT subjects, and T2D 
patients. Three polymorphisms conferred susceptibility to T2D. SNP rs1143699 was 
associated with an increased risk of T2D in male patients carrying the C/C genotype. 
SNPs rs4807015 and rs1978237 were associated with an increased risk of T2D in 
both male and female patients.  
Zn-α2-glycoprotein 1 (AZGP1) (paper II) is a novel adipokine that may be involved in 
the regulation of body weight. Through microarray gene expression we found that the 
AZGP1 gene was down-regulated 3.9-fold in subcutaneous (S.C.) abdominal fat of 
NGT obese subjects compared to lean. We also showed that AZGP1 is significantly 
decreased in S.C. abdominal and omental fat but not in S.C. thigh fat. Genotyping of 
AZGP1 polymorphisms in NGT lean subjects, NGT obese subjects, IGT obese subjects 
and T2D patients revealed that SNP rs2525554 is associated with obesity. Association 
with the T-allele was evident for BMI, waist circumference, waist-hip ratio and 2h 
glucose. Decreased AZGP1 expression in obese subjects was found to correlate with 
their higher frequency of risk allele T in rs2525554.  
Alpha 2-adrenergic receptors are involved in insulin secretion and lipolysis. We 
evaluated association for the adrenergic receptor alpha 2A (ADRA2A) gene (paper III) 
with obesity and/or T2D in our cohort. Data indicate that two SNPs, rs553668 and 
rs521674, are associated with disease. rs553668 in men is linked to obesity and 
rs521674 in women to obesity and possibly T2D.  
Adenylate cyclase 3 (AC3) (paper IV) is expressed in pancreatic islets, brain, heart, 
kidney, liver, lung and skeletal muscle. A previous study from our laboratory 
demonstrated that the AC3 mRNA was overexpressed in the pancreatic islets of the 
GK rat. In our association study for the AC3 gene it was found that SNPs rs2033655 
and rs1968482 are strongly associated with obesity in NGT subjects and T2D 
patients. A diplotype analysis with the associated polymorphisms predicted a 
significant association with BMI in obese subjects.  
The results from the four candidate gene association studies have generated knowledge 
of their role in obesity and T2D development. RPTPσ seems to be involved in T2D 
whereas AZGP1, ADRA2A and AC3 are most likely linked to obesity. Two studies 
also revealed gender specific associations. The associated variants need to be 
investigated further regarding function, gene-gene and gene-environment interactions. 
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1 BACKGROUND 
 
1.1 TYPE 2 DIABETES 
The worldwide prevalence of diabetes is predicted to increase from 2.8% in 2000 to 
4.4% in 2030 with over 350 million people affected 1. There are two common forms of 
diabetes, type 1 diabetes (T1D) where the production of insulin is lacking and type 2 
diabetes (T2D) caused by β-cell dysfunction and insulin resistance. Both forms leads to 
hyperglycemia and when poorly treated to increased urine production, compensatory 
thirst and excessive fluid intake, blurred vision, lethargy and changes in energy 
metabolism. T2D may be provoked by pregnancy, medications and organic pollutants2. 
Approximately 85-90% of those affected by diabetes have T2D that is a late-onset 
disease becoming more prevalent due to an aging population and an increase in obesity. 
It is alarming that obese children and young adults are developing T2D 3. About 80% 
of T2D patients are associated with obesity and physical inactivity 4. Our research 
group has previously shown that other factors such as tobacco use 5, psychosocial- 6 
and work-stress 7 are associated with increased risk of T2D. Another form of diabetes is 
maturity onset diabetes of the young (MODY). It is characterized by young-age onset, 
autosomal dominant inheritance and lack of association with obesity. To date, eight 
genes have been described for MODY. 
 
There are two conditions which usually precede T2D. They are therefore often called 
pre-diabetes. In impaired glucose tolerance (IGT) an oral glucose load renders plasma 
glucose levels between normal glucose tolerance and diabetes, and in impaired fasting 
glucose (IFG), the fasting plasma glucose is in between normal and diabetic values.  
 
Glucose homeostasis is strongly accompanied by the interplay between insulin 
secretion and insulin actions. During fasting, glucose is mainly produced by the liver 
and about 50% of it is utilized by the brain. The rest is taken up by other tissues. A 
normal liver can increase glucose production ≥ 4-fold. In this state plasma insulin is 
low not to restrain glucose production by the liver. A drop in glucose level also results 
in the release of glucagon from pancreatic α-cells, which stimulates the conversion of 
glycogen to glucose. After a meal, insulin levels are increased and glucose production 
is decreased. The normal pancreatic β-cell can adapt to changes in insulin action i.e. a 
decrease in insulin sensitivity, insulin resistance, is followed by upregulation of insulin 
secretion and the other way around 8-10. When the adaptation is insufficient, individuals 
will develop pre-diabetes or T2D 11. Thus, β-cell dysfunction is critical for the 
pathogenesis of T2D 12. Insulin resistance occurs when the effects of insulin are 
abnormal for both glucose disposal in skeletal muscle and/or endogenous glucose 
production in the liver 11 13. For a schematic overview of the above mentioned 
mechanisms, see Figure 1. 
 
T2D complications can be divided into macro- and microvascular. The macrovascular 
complications occur in larger blood vessels and can lead to cardiovascular disorders 
including stroke, myocardial infarction and peripheral vascular disease. These 
complications can happen even with small increases in blood glucose levels. Micro-
vascular complications occur in small blood vessels in the eyes, kidneys and peripheral 
nerves. They are a reflection of the duration and severity of hyperglycemia. The main 
therapy goal for diabetes is to prevent complications. Besides treatment of hyper-
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glycemia patients are usually given anti-hypertensive and anti-hyperlipidemic drugs. 
Exercise and diet are important for the treatment of T2D and allow simpler regimens to 
be used to control blood glucose levels 14. 
 
 
 
Figure 1. T2D major metabolic defects: increased level of blood glucose is a consequence of impaired 
insulin action and/or insulin secretion. Insulin resistance is evident when the effects of insulin are 
abnormal for glucose uptake in skeletal muscle and for glucose production in the liver. TG: triglyceride, 
VLDL: very low density lipoprotein . 
 
T2D has a strong genetic component which may account for differences in prevalence 
between ethnic groups, higher concordance rate among monozygotic than dizygotic 
twins and a sibling risk ratio of about 3.5 15. The lifetime risk of T2D is 7% in the 
general population 16. A positive family history of T2D confers an increased risk for 
disease 17 with a 40% risk to develop T2D in first degree relatives. The risk increases to 
70% if both parents have diabetes 16.  
 
1.2 OBESITY 
Overweight and obesity are defined as abnormal or excessive fat accumulation that 
presents a risk to health. A common measure of obesity is body mass index (BMI). A 
person with a BMI of ≥ 30 is generally considered obese. A person with a BMI ≥ 25 is 
considered overweight. Overweight and obesity are major risk factors for a number of 
chronic diseases, including diabetes, cardiovascular diseases and cancer 18. Obesity also 
contributes to shorter lifespan, depression and decreased quality of life 19-20. Over-
weight and obesity are now dramatically on the rise in low- and middle-income 
countries. The fundamental cause of obesity and overweight is a lack of energy balance 
between calories consumed and expended. Increases in overweight and obesity are 
attributable to a global shift in diet towards increased intake of energy-dense foods and 
a trend towards decreased physical activity. 
 
Global projections estimate 1.12 billion individuals to be obese by the year 2030 21. The 
rapid growth of obesity have occurred in both adults and children 22. Obesity is a major 
contributor to morbidity and mortality across the world, surpassing drinking and 
smoking in its negative effects on health. This will have negative effects on life 
expectancies of generations born after the rise of the obesity epidemic 23. The obesity 
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epidemic during the last decades can not only be explained by our environment. Our 
genetic background also contributes to this problem 24. 
 
The evidence for a genetic component in obesity is strong 25-26. The evidence include 
differences in prevalence between ethnic groups 27-28, higher fat concordance in 
monozygotic compared to dizygotic twins 29-30 and 30-70% BMI heritability between 
individuals 31-34. There are several theories explaining the genetics of obesity but there 
is no current consensus in the area as a consequence of the complex nature of obesity 
susceptibility 35. Common obesity is polygenic with no simple Mendelian inheritance 
pattern 35. The theories available overlap to a great extent, but differ in their views of 
key tissue involved. First, as mentioned previously, obesity has been viewed mainly as 
a disease of energy balance due to an excess energy intake or a decreased energy 
expenditure. Second, obesity is also seen as a disorder of the adipocyte as it has a 
mechanism of fat storage and mobilization. Adipose tissue has been recognized as 
having an independent endocrine role that can result in an inflammatory response with 
increased risk of T2D and cardiovascular disease, leading to increased morbidity and 
early mortality 36. Adipose tissue affects energy homeostasis and cardiovascular health 
by releasing adipokines that regulate energy expenditure, food intake, insulin sensitivity 
and inflammation 36. Third, a new view of obesity as a neurobehavioral disorder has 
emerged with the control of appetite and food intake involved in obesity pathogenesis 
35 37.  
 
Obesity is strongly associated with insulin resistance, i.e. there is suppressed or delayed 
responses to insulin in insulin sensitive tissues. Hormones, cytokines and metabolic 
fuels from the adipocyte can diminish insulin action. Large adipocytes in obese subjects 
are resistant to insulin suppression of lipolysis, particularly in visceral fat. This all 
results in elevated levels of fatty acids and glycerol, which exacerbate insulin resistance 
in skeletal muscle and liver 38.  
 
1.3 GENETICS OF COMPLEX DISEASES 
Many human diseases have a genetic component. When searching for  genetic variants 
that predispose to common disease the strategy depends on the underlying genetic 
model, which is often unknown 39. Polygenic diseases often cluster in families and are 
strongly inherited but do not show simple heredity patterns. It is likely that both 
common and rare variants are contributing to common disease 40-42. Human genetic 
variation occurs as single nucleotide polymorphisms (SNPs) and specific combinations 
of alleles are known as haplotypes. SNPs are single changes of base pairs. They cover 
about 90% of the human sequence variation and are considered as major determinants 
of predisposition to complex diseases. Besides these sequence variabilities other 
epigenetic events (histone acetylation, RNA interference and DNA methylation) add to 
the different complex gene regulation in individuals 43. 
 
1.3.1 Type 2 diabetes 
Polygenic or multi-factorial T2D is a result of the interaction between many genes 
and the environment. The susceptibility to T2D is associated with frequent 
polymorphisms that influence expression of genes in regulatory parts and create 
amino acid changes in proteins 44-45. Such alleles of genetic variants are present in 
healthy subjects and T2D patients with different frequencies and are associated with a 
limited increase in the risk of developing disease. The SNPs are considered as 
susceptibility variants but they are not causative factors. Polygenic T2D is normally 
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diagnosed in the later stages of life 46. The complex nature of T2D makes it harder to 
identify individual genes associated with increased risk of diabetes. To date, genetic 
studies have together identified 27 confirmed and potential common variants 
associated with T2D 47. Eight of these loci appear to be involved in β-cell insulin 
secretion and response to an increased insulin resistance or obesity. One gene is 
involved in insulin sensitivity, another in glucose transport and two are related to 
obesity. The rest have unknown roles 48. A major T2D susceptibility gene, 
transcription factor 7-like 2 (TCF7L2), has been identified and shown to account for 
20% of T2D cases 49. The gene is associated with alterations in insulin secretion. It 
has also been found that common variants in the TCF7L2 gene can be used together 
with major histocompatibility complex, class II, DQ beta 1 (HLA-DQB1) genotyping 
to distinguish between young adults with antibody-positive and antibody-negative 
diabetes. HLA-DQB1 is a gene that is associated with an increased risk of developing 
T1D. This is not possible in middle-aged diabetic patients, suggesting that middle-
aged antibody-positive patients are different from young antibody-positive patients 
and that T1D in middle-aged patients shares genetic features with type 2 diabetes 50.  
 
1.3.2 Obesity  
Obesity is a heterogeneous disease and many common genetic variants contribute to the 
risk of developing this disorder, each conferring a modest odds ratio. The obesity risk is 
greatly affected by functional genetic variations and environmental factors, as in the 
case with T2D. Gene-environment interactions means that the combined effect of 
genotype and environment results from the additive or multiplicative effects of both 
factors 43. Environmental factors are modifiable whereas genetic factors are not 51. In 
the majority of patients with obesity, multiple genes interact with many environmental 
factors over time. As the technology advances the list of susceptibility genes to obesity 
grows. The influence of genes that have been associated with obesity is modest 52. The 
strongest associated SNP in obesity is rs9939609 in the fat mass and obesity associated 
gene (FTO). This variant has about 1% effect on the variance seen with BMI 53. 
 
1.3.3 Study approaches 
There are three basic strategies for disclosing and characterizing genes that influence 
complex diseases: genome-wide linkage scan, candidate gene analysis and genome-
wide association studies. Each of these strategies has unique advantages, features, 
motivations and problems associated with them and will therefore be discussed 
separately.  
 
1.3.3.1 Genome-wide linkage scan 
Genome-wide linkage scan is a method used to search for possible genes that are 
responsible for diseases in human. It is family-based and investigates if any genetic 
markers (microsatellites or SNPs) from a set of markers that spans the whole genome 
co-segregate with disease phenotypes. It is based on finding a statistical signal that 
gives the probability of co-segregation of a disease with a chromosomal locus. If a 
signal is present it is said to be linked to the trait investigated. When a chromosomal 
region has been identified the next step is to search within this region for recombination 
events in one or several families 54-55. The search for mutations is performed in all 
genes located in the particular region despite their biological role. This step is known as 
positional cloning. Sequence mutations are checked for their role in disease and this is 
done by verifying if they co-segregate with disease in linked families. One also looks at 
the mutations in the control group and tries to define their role in disease by biological 
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experiments 56. Supports for disease association are segregation with disease in 
families, lack of mutation in controls or alteration of protein function. One example of 
successful gene identification by this approach is the MODY3 story 56-57. It has not 
been as fruitful in finding T2D loci, with the exception of calpain 10 58-59 and TCF7L2 
49. More than 60 genome scans have been performed for obesity and 250 quantitative 
trait loci (QTLs) were identified by 2006 60. A meta-analysis of 37 published studies 
including more than 31,000 subjects did not detect strong evidence for BMI or BMI-
defined obesity at any locus 61. Linkage analysis is only successful for common 
diseases when variants have strong effect in one gene. Since replication of loci from 
common disease has been tough, it further suggests that these variants only have small 
genetic effects.  
 
1.3.3.2 Candidate gene association  
This approach examines specific genes with a potential role in the disease 
pathophysiology. Candidate genes are selected based on their role in biological 
pathways relevant for a phenotype of interest. It has the advantage of a short-range 
effect compared to linkage and it can be carried out in unrelated individuals, which are 
normally easier to recruit than families. The candidate gene approach has broadly been 
used to study the genetic basis of pharmacogenomic traits. Most success has been 
found in cancer where positive impact on patient care is seen 62. Genetic association 
studies are much more powerful than linkage studies in finding common variants of 
modest effect 63. Many candidate genes are derived from animal models, which are 
extremely useful since there is limited availability of human tissue. Today there are 
animal models of insulin resistance, obesity, β-cell dysfunction, impaired glucose 
homeostasis, insulin secretion and T2D. They provide important insights into human 
disease and are making great progress in identifying genes that may be functionally 
essential in the pathophysiology of obesity and T2D 64. Two T2D genes that have been 
detected by candidate-gene association are the peroxisome proliferator-activated 
receptor gamma (PPARG) gene 65 and the potassium inwardly rectifying channel, 
subfamily J, member 11 (KCNJ11) 66. Both genes are involved in targets of T2D drugs.  
 
1.3.3.3 Genome-wide association study 
Genome-wide association study (GWAS) is a hypothesis-free method of investigating 
the association between common genetic variation and disease. This type of study 
requires a dense set of markers (i.e. SNPs) that cover a great proportion of common 
variants across the genome and large number of subjects 35. GWAS are very similar to 
genome-wide linkage as far as being a hypothesis-generating approach. It involves 
screening of the whole genome and the aim is to identify new genetic variants 
associated with disease. GWAS uses a case-control design to increase the chances of 
recruiting large numbers of subjects and also to gain statistical power. The statistical 
analyses identify top hits for SNPs and candidate genes which are then targeted for 
additional genotyping in a larger independent cohort of cases and controls for 
replication 35. 
 
Recently, there have been many advances that have made GWAS successful. One of 
them is the sequencing of the human genome 67 and the International HapMap project 
68-69. It has increased our knowledge of common genetic variation and linkage 
disequilibrium (LD). The other is the development of high-throughput genotyping. 
Today it is possible to genotype millions of SNPs. The SNP chips available for this 
technique capture more than 80% of the common genetic variations reported in 
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HapMap 70. The first GWAS of diabetes was published in 2007 71 and soon after that 
several groups simultaneously published GWAS 72-75. 
 
There are limitations of GWAS. It is based on the common disease-common variant 
hypothesis, which means that common diseases are caused by a few common variants 
instead of many rare variants. This theory has recently been discussed 76. It is of interest 
to note that the majority of the results from GWAS are for markers that are not in 
known genes 35. Identification of cases and controls for GWAS also has limitations. If 
young subjects are used their metabolic function can be normal at the time of the study 
but risk allele carriers may develop age-related phenotypes later in life 77. Several loci 
that confer predisposition to T2D have recently been discovered and replicated by a 
number of genome-wide association studies 71-75. In general, the GWA approach has 
increased the number of obesity- and T2D-associated markers substantially. Many of 
the associations found by GWAS have poorly understood functions. Now it is 
important to identify causal variants and distinguish their biological role in disease.  
 
1.4 IMPACT OF CANDIDATE GENES ON OBESITY AND TYPE 2 
DIABETES 
This thesis is focused on the candidate gene approach. It includes genetic association 
studies of obesity and T2D. Candidate genes are derived from previous studies by our 
group. They are also selected based on their role in biological pathways relevant for 
pathogenesis of obesity and T2D. The candidate genes studied are described in the 
same order as in the list of publications.  
 
1.4.1 Receptor protein tyrosine phosphatase σ 
Receptor protein tyrosine phosphatase sigma (RPTPσ) is a member of the leukocyte 
antigen-related (LAR) RPTP family, which has been suggested to act in key steps of 
neural development and also in diabetes and cancer 78-79. LAR, a protein closely related 
to RPTPσ, has negative regulatory effects in the insulin signaling pathway when it is 
over-expressed 80. The RPTPσ gene gives rise to several different distinct isoforms 81. 
PTPs are key regulators of the insulin receptor signal transduction pathway and the 
RPTPσ gene has been shown to be highly expressed in insulin target tissues, such as 
liver, adipose tissue, skeletal muscle, and endothelial cells 82. In humans, the RPTPσ 
gene is located on chromosome 19p13.3, a region that may influence traits underlying 
lipid abnormalities associated with T2D 83.  
 
We have previously demonstrated that the RPTPσ gene is over-expressed in pancreatic 
islets and liver of spontaneously diabetic Goto–Kakizaki (GK) rats that is an animal 
model of T2D mainly characterized by impaired insulin secretion. The GK rat is non-
obese and develops mild hyperglycemia early in life. Its glucose intolerance is most 
likely due to impaired β-cell function together with polygenic inheritance 84. When islet 
RPTPσ was inhibited by antisense, improved glucose-induced insulin secretion was 
seen in GK islets 85. In addition, RPTPσ knockout (-/-) mice has shown decreased 
plasma glucose and insulin levels in the fasted state when compared with wild-type 
controls. The mice also had increased whole-body insulin sensitivity, suggesting that 
RPTPσ affects insulin signaling in insulin-sensitive tissues 86. Until now, there has not 
been a genetic report of RPTPσ in T2D patients.  
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1.4.2 Zinc-α2-glycoprotein 1  
Zn-α2-glycoprotein 1 (ZAG/AZGP1) is a 43-kDa soluble protein that recently has 
been classified as a novel adipokine and appears to play many important roles in the 
human body. AZGP1 expression is regulated by TNF-α and the PPARγ receptor 87-89. 
The gene is 9.3 kb long, includes 4 exons and is located on chromosome 7q22.1 90-91. 
AZGP1 is homologous to lipid mobilizing factor (LMF), which shares similar 
chemical identity and biological activity with AZGP1. Both proteins have been 
associated with loss of adipose tissue stores in cancer cachexia and shown to 
stimulate lipolysis by adipocytes both in vitro and in vivo 92-93. AZGP1 is thought to 
be involved in regulation of body weight and genetically affected obesity 94. It has the 
ability to induce uncoupling protein (UCP) expression in brown adipose tissue and 
skeletal muscle 95. This process is most likely related to the loss of adipose tissue. 
Gohda et al. reported AZGP1 to be a strong candidate gene for obesity using 
genetically homogenous T2D KK/Ta mice 96. The KK/Ta strain is a polygenic mouse 
model for the common form of T2D associated with obesity in humans. Another 
study has demonstrated that AZGP1 deficient mice are overweight and their 
adipocytes appear to have decreased lipolysis 97. Treatment with AZGP1 stimulates 
lipolysis in both human and mouse adipocytes and reduces body fat in normal and 
ob/ob mice 98. Recently, studies have shown decreased serum levels of AZGP1 in 
obese subjects99-100.  
 
1.4.3 Adrenergic receptor α 2A  
The sympathetic nervous system (SNS) plays an important role in regulating 
metabolism of glucose and lipids 101. In addition to direct effects on metabolic substrate 
fluxes, SNS modulates release of insulin and glucagon which in turn regulate 
metabolism of glucose, lipids and protein. Catecholamines increase glucose levels by 
stimulating glycolysis and by decreasing peripheral glucose uptake as well as by 
inhibiting insulin release and stimulating glucagon secretion. Catecholamines are the 
most important regulators of lipolysis in human adipose tissue 102-103. Thus, stimulation 
of β-adrenergic receptors enhances lipolysis whereas stimulation of α2-adrenergic 
receptors inhibits lipolysis 102-103. Insulin inhibits catecholamine-stimulated lipolysis by 
reducing the effects of adrenaline on β2- and activating α2-adrenergic receptors in 
adipocytes 104. Low activity of the SNS is a risk factor for weight gain and obesity 105. 
The sympathetic tone later increases in obese individuals and this will have adverse 
effects on pancreatic function and may contribute to the abnormal glucose-induced 
insulin secretion in obese subjects106. Increased activity of SNS also contributes to 
development of hypertension and elevated cardiovascular risk in obese subjects 107. 
 
As described above catecholamines exert an important physiological role by α2-
adrenergic receptor mediated inhibition of insulin secretion in animals and in man. In 
contrast, stimulation of β2-adrenergic receptors enhances insulin release 108-110. 
Increased expression of α2-adrenergic receptors in β-cells can cause alterations in 
insulin secretion regulation and contribute to etiology of T2D 111. α2A-adrenergic 
receptor deficient mice exhibit increased plasma insulin levels, reduced blood glucose 
levels and improved glucose tolerance 112.  
 
Polymorphisms in the human α2A-adrenergic receptor gene have been identified and 
associated with obesity 113-116, elevated glucose levels 117, reduced insulin secretion and 
increased risk of T2D 118, hypertension 119, cardiovascular diseases 120 and attention-
deficit hyperactivity disorder (ADHD) 121. However, the genetic susceptibility with 
obesity has only been investigated in a limited number of individuals.  
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1.4.4 Adenylate cyclase 3  
Adenylate cyclases (ACs) are enzymes that catalyze the synthesis of cyclic-adenosine 
mono-phosphate (cAMP) from adenosine tri-phosphate (ATP). At least nine closely 
related isoforms of ACs have been cloned and characterized in mammals 122. AC3 is 
expressed in pancreatic islets, brain, heart, kidney, liver, lung and skeletal muscle. The 
protein consists of two transmembrane regions, each containing six predicted 
membrane spanning helices, and two cytoplasmic regions 122. It is located on 
chromosome 2p23.3 123. 
 
The GK rat exhibits a markedly reduced glucose-induced insulin release in vivo and in 
isolated perfused pancreas and isolated islets 124-127. A previous study from our 
laboratory demonstrated that AC3 mRNA was over-expressed in pancreatic islets of the 
GK rat, which was caused by two point mutations at in the promoter region 128. The 
insulinotropic effect of forskolin in GK rat islets is associated with an enhanced cAMP 
generation and with over-expression of AC3 mRNA 129. Moreover, liver AC activity 
was increased in the membranes of male ob/ob mice in comparison to lean control mice 
130. These findings suggest a role for the AC3 gene in the pathogenesis of T2D and 
obesity. There is no reported study of genetic association with the AC3 gene in T2D, 
obesity or metabolic syndrome.  
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2 AIMS 
 
The overall aim of this thesis was to find genetic association of SNPs in the selected 
candidate genes and to better understand their role in the development of obesity and 
T2D. 
 
Paper I - RPTPσ 
• To evaluate the genetic influence of RPTPσ polymorphisms in development of 
T2D. 
 
Paper II - AZGP1 
• To investigate AZGP1 differential expression in subcutaneous (S.C.) 
abdominal, omental and thigh adipose tissue to establish the role of AZGP1 in 
obesity. 
• To study AZGP1 polymorphisms in association with obesity and/or T2D.  
 
Paper III - ADRA2A 
• To establish the role of ADRA2A genetic variation in T2D and/or obesity.  
 
Paper IV- AC3 
• To evaluate the association of AC3 genetic variation in T2D and/or obesity.  
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3 SUBJECTS AND METHODS 
 
3.1 SUBJECTS 
3.1.1 Stockholm diabetes prevention program  
Stockholm diabetes prevention program (SDPP) is a study which includes participants 
from four (in men) and five (in women) municipalities in the Stockholm region 
(Sigtuna, Tyresö, Upplands-Bro, Värmdö (Upplands-Väsby)). The participants were 
aged 35-56 years when entering the study. The study consists of a baseline study in 
men 1992-1994 and in women 1996-1998. A follow-up study in about 70% of the 
baseline participants was conducted 8-10 years later 6-7 131-132. The subjects underwent a 
standardized 75 g oral glucose tolerance test (OGTT) after an overnight fast. Venous 
blood samples were taken before and 2 hours after glucose ingestion. Abnormal 
glucose regulation was diagnosed according to the World Health Organization criteria 
(WHO,1998) 133. Current standard definitions of overweight and obesity were used 
according to the Center for Disease Control (CDC, 1998) and World Health 
Organization (1997) 134-135. All individuals were unrelated. Among the included 
subjects 50% had a positive family history of diabetes (FHD) where FHD was defined 
as having at least one first-degree relative (parent or sibling) or at least two second-
degree relatives (grandparents, aunts or uncles). All clinical data in NGT controls (with 
no FHD), IGT obese and T2D subjects were used from the baseline study (for those 
who were obese/T2D at baseline and those who became obese/T2D between baseline 
and follow-up studies i.e. incident cases) or from the follow-up study (for those who 
were diagnosed obese/T2D at follow-up). Baseline data for incident cases were used to 
avoid the influence of lifestyle changes and/or anti-diabetic treatment on phenotypes. 
Informed consent was obtained from all participants before initiation of the study. The 
procedures followed were in accordance with the declaration of Helsinki II and 
approved by the ethics committee of Karolinska Hospital.  
 
3.1.2 Subjects for microarray analysis 
A total of 21 men (46-63 years) with NGT were studied. The obese subjects (n=11) had 
a BMI > 30 kg/m2. The lean subjects (n=10) had a BMI of 20-23 kg/m2 and no FHD. 
They were matched regarding age to the obese group. All individuals were Swedish 
Caucasians collected from SDPP 131-132 136. After an overnight fast, adipose tissue 
biopsies of 3-4 g were taken surgically from the subcutaneous (S.C.) abdominal region 
with local anesthesia and then frozen until gene expression analysis. A whole blood 
sample was taken from the subjects and was used for DNA extraction and variation 
screening. All participants gave their informed consent and the ethics committee of 
Karolinska Institutet approved the experimental protocol.  
 
BMI was calculated as weight (in kg) divided by the square of height (in m2). Body 
composition was measured by dual energy X-ray absorptiometry (DEXA) using a total 
body scanner (DPX-L; Lunar Radiation, Madison, WI, USA) and maximal oxygen 
uptake (VO2max) using a bicycle ergometer exercise test. Whole body insulin 
sensitivity was measured using the euglycemic hyperinsulinemic clamp technique 137-
138. A 2h 75 g OGTT was performed after a 12 h overnight fast. Diabetes was defined 
according to the criteria of the WHO 1998 133. Anthropometric and metabolic 
characteristics for each subject group are given in Table 1. As expected the lean and 
obese groups differed with regard to BMI, WHR, % total fat and % truncal fat but not 
   11 
for age and VO2 max. The obese had lower insulin sensitivity than their non-obese 
counterparts.  
 
Table 1. Data on subjects used for microarray gene expression profiling 
Clinical parameters Lean (n=10) Obese (n=11) P-value 
Age 54.6±6.3 56.6±2.7 0.397 
BMI (kg/m2) 22.2±1.3 33.1±2.2 <0.001 
Waist-hip ratio 0.87±0.0 1.0±0.1 <0.001 
Fasting plasma glucose (mmol/l) 4.7±0.3 5.0±0.3 0.073 
2 h plasma glucose (mmol/l) 4.5±0.5 5.4±0.9 0.014 
M-value clamp 8.7±1.8 4.2±1.3 <0.001 
VO2 max 41.0±6.2 37.6±6.4 0.338 
Total fat (%) 15.0±3.7 28.9±3.0 <0.001 
Truncal fat (%) 44.0±7.8 52.8±2.9 0.012 
All data are means ± SD. P-value was calculated by a Student’s t-test.  
 
3.1.3 Subjects for gene expression by real-time PCR 
Samples used for microarray analysis were not available for real-time PCR due to 
limited amounts of RNA. Instead a total of 10 obese and non-obese subjects (41-82 
years) were studied during cholecystectomy. The obese subjects (n=6, 2 men/4 women) 
had a BMI range of 31.1-34.2 kg/m2. The lean subjects (n=4, 1 man/3 women) had a 
BMI range of 20.7-25.0 kg/m2 and no family history of diabetes. They were matched 
regarding age to the case group. All individuals were Swedish Caucasians collected 
from Ersta Hospital, Stockholm, Sweden. After an overnight fast, adipose tissue 
biopsies of 3-4 g were taken surgically from the S.C. abdominal and thigh regions as 
well as omental (visceral) fat and then frozen until gene expression analysis. All 
participants gave their informed consent and the procedures followed were in 
accordance with the declaration of Helsinki II and approved by the ethics committee of 
Karolinska Hospital.  
 
3.2 METHODS 
3.2.1 DNA extraction  
DNA was extracted from peripheral blood using Puregene DNA purification kit 
(Gentra Systems, Minneapolis, MN, USA). The Gentra Systems Puregene DNA 
purification kit is used for purifying genomic, mitochondrial, and viral DNA. It 
includes alcohol and salt precipitation. The first step is to lyse cells with an anionic 
detergent in the presence of a DNA stabilizer that inhibits DNase activity. After that 
RNA and proteins are digested and removed together with other contaminants by salt 
precipitation. The DNA is then precipitated with alcohol and dissolved in a DNA 
stabilizer. 
 
3.2.2 SNP selection and validation  
We have selected SNPs from the National Center for Biotechnology Information 
(NCBI) (USA; http://www.ncbi.nlm.nih.gov/SNP/) database based on validation status, 
region, and function. SNPs chosen were picked to cover the whole genes. The Tagger 
program from the International HapMap project was also used to select and evaluate 
tagSNPs from genotype data in HapMap 139. Here, pair wise tagging was used together 
with an r2 cutoff of 0.8 and a minor allele frequency (MAF) of 5%. The majority of the 
chosen SNPs were captured by tagger. SNPs were also chosen based on previously 
studied populations and results obtained during variation screening (papers II and IV). 
To validate the selected SNP genotyping assays in our population we used 32 Swedish 
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DNA samples including 16 obese subjects and 16 NGT controls. SNPs representing at 
least 4-5% allele frequencies were used for further genotyping in the larger sample set.  
 
3.2.3 Genotyping 
3.2.3.1 Dynamic allele-specific hybridization 
High throughput genotyping was performed by dynamic allele-specific hybridization 
(DASH) (MCA System, ThermoHybaid, UK) 140. The DASH principle consists of 
dynamic heating and monitoring of DNA denaturation. No additional enzymes or 
reaction steps are involved. The DASH-assay is carried out in a micro-titer plate format 
and uses fluorescence signal detection. The target sequence is amplified by PCR. One 
primer is labeled with biotin. The biotinylated product strand is bound to a streptavidin-
coated micro titer plate well, and the non-biotinylated strand is rinsed away with 
NaOH. An oligonucleotide probe, specific for one of the alleles, is hybridized to the 
target at low temperature. This forms a duplex DNA region that interacts with a double 
strand-specific intercalating dye. Upon excitation, the dye emits fluorescence 
proportional to the amount of double-stranded DNA (probe-target duplex) present. The 
sample is then steadily heated while fluorescence is continually monitored. A rapid fall 
in fluorescence indicates the melting temperature of the probe-target duplex. A single-
base mismatch between the probe and the target results in a dramatic lowering of 
melting temperature (Tm), which is detected. PCR-DASH assay design and SNP 
genotyping protocol were used as described previously 141.   
 
3.2.3.2 TaqMan allelic discrimination  
TaqMan Allelic Discrimination is a probe technology that uses the 5´-3´ nuclease 
activity 142 of AmpliTaq Gold ® DNA Polymerase to allow detection of the PCR 
product by releasing a fluorescent reporter. AmpErase ® UNG is required for the 
prevention of PCR product carryover 143. The allelic discrimination assay requires two 
probes, one for each allele. Each probe consists of an oligonucleotide with a 5´-reporter 
dye and a 3´-quencher dye. TET (tetrachlorofluorescein) is covalently linked to the 5´ 
end of the probe for the detection of allele 1. FAM (carboxyfluorescein) is covalently 
linked to the 5´-end of the probe for the detection of allele 2.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. The mechanism of TaqMan Allelic Discrimination. The 5´–3´ nuclease activity of AmpliTaq 
Gold DNA polymerase during the extension phase of PCR is shown 144-145. Picture from TaqMan allelic 
discrimination protocol 4303267D. 
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The reporters are quenched by TAMRA (tetramethylrhodamine), which is attached at 
the 3´-end of each probe. When the probe is intact, the close distance of the reporter 
dye and quencher dye results in suppression of reporter fluorescence. Forward and 
reverse primers hybridize during PCR to a specific sequence of the target DNA. The 
TaqMan probe hybridizes to a target sequence within the PCR product. The AmpliTaq 
Gold polymerase cleaves the TaqMan probe. The reporter- and quencher-dye are 
separated when the probe is cleaved ad this results in increased fluorescence from the 
reporter, see Figure 2. The 3´ end of the TaqMan probe is blocked to prevent extension 
of the probe during PCR. This event occurs in every PCR cycle and does not interfere 
with the exponential increase of product. The increase in fluorescence is measured, and 
is a direct consequence of target amplification during PCR. Both primer and probe 
must bind to their targets for amplification and cleavage to occur. The fluorescence 
signals are created only if the target sequences for the probes are amplified during PCR 
146-147. Therefore, non-specific amplification will not be detected. High throughput 
genotyping was performed by TaqMan allelic discrimination (ABI 7300, Applied 
Biosystems, USA)148-149. TaqMan assay design and SNP genotyping protocols were 
used as described previously 141 150.  
 
3.2.3.3 Pyrosequencing  
To confirm our genotyping data in paper IV, particular for those SNPs that were not 
in Hardy–Weinberg equilibrium (HWE), we have used another high-throughput 
genotyping method, that is pyrosequencing (PSQ96t, Pyrosequencing AB, Sweden) 
using the same primers as in DASH. Pyrosequencing is a sequencing method based 
on real-time monitoring of DNA synthesis. It is a four-enzyme DNA sequencing 
technology detected by bioluminescence 151. In the first step, a primer is hybridized to 
a single-stranded PCR product and incubated with the enzymes, DNA polymerase, 
ATP sulfurylase, luciferase, and apyrase as well as the substrates, adenosine 5' 
phosphosulfate (APS), and luciferin. In step 2, the first deoxyribonucleotide 
triphosphate (dNTP) is added to the reaction. If the dNTP is complementary to the 
base in the template strand it is incorporated. The incorporation is catalyzed by DNA 
polymerase. Every incorporation is followed by release of pyrophosphate (PPi) in a 
quantity reflecting the amount of incorporated nucleotide. In step 3, ATP sulfurylase 
converts PPi to ATP in the presence of adenosine 5' phosphosulfate (APS). The ATP 
drives the luciferase-mediated conversion of luciferin to oxyluciferin that generates 
visible light in proportion to the amount of ATP. The light is detected by a charge 
coupled device (CCD) chip and seen as a peak in the raw data output (Pyrogram). The 
height of each peak is proportional to the number of nucleotides incorporated. In step 
4, apyrase, a nucleotide-degrading enzyme, degrades unincorporated nucleotides and 
ATP. When degradation is complete, another nucleotide is added. In step 5, addition 
of dNTPs is performed sequentially. It should be mentioned that deoxyadenosine alfa-
thio triphosphate (dATP·S) is used as a substitute for the natural deoxyadenosine 
triphosphate (dATP) since it is efficiently used by the DNA polymerase, but not 
recognized by the luciferase. As the process continues, the complementary DNA 
strand is built up and the nucleotide sequence is determined from the signal peaks in 
the Pyrogram.  
 
SNP determination starts with analysis of nucleotide(s) preceding the investigated 
position. The advantage of using cyclic addition of nucleotides is that it results in 
three distinctive patterns at the polymorphic sites due to non-synchronized 
extensions. In contrast, the sequential nucleotide addition generates differences in 
three peak positions and is designed so that the individual allele extensions are in 
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phase. Thereafter, further nucleotide additions will give the consensus sequence of 
the target and can improve raw data interpretation 152.  
 
3.2.4 Microarray gene expression profiling 
The microarray technique has made it possible for global measurement of gene 
expression on mRNA level (transcript level). This experiment uses oligonucleotide 
arrays, which are developed by Affymetrix, Inc (Santa Clara, CA, USA). The output 
from the arrays can be used in many analysis programs, where genes can be selected, 
filtered and clustered for further examination. Microarray is a specific, sensitive and 
reproductive technique. The human genome U95_Av2 gene chips contain probe sets 
interrogating approximately 12 600 gene transcripts 153. Microarray expression 
profiling consists of the following steps 154: 
 
- Target preparation – dsDNA is synthesized from total RNA, isolated from 
tissue. In vitro transcription (IVT) is then performed to generate biotin-labeled 
cRNA from cDNA. 
- Target hybridization – A hybridization cocktail is prepared and it includes 
probe array controls, fragmented target, bovine serum albumin (BSA) and 
herring sperm DNA. 
- Probe array washing and staining. 
- Probe array scan – After washing and staining the array is scanned. Each 
probe array is scanned twice and the software combines the two images. It 
also defines the probe cells and gives the intensity for each cell. This double 
scan has the advantage that it improves assay sensitivity and it also reduces 
background noise. 
- Data analysis – Initial data is analyzed using Microarray Suite Expression 
Analysis. The data is then transferred to another program for further analysis. 
Total RNA from 500-1000 mg S.C. abdominal adipose tissue was isolated using the 
TriZol reagent (Life Technologies, Gaithersburg, MD) and the Fast RNA green 
(BIO101, Vista, CA) kit according to the manufacturer’s protocols. The RNA samples 
were purified using the RNeasy kit (Qiagen, Valencia, CA), quantified with a 
spectrophotometer. Absorbance at 260 nm and 280 nm were used for determination of 
sample concentration and purity. Samples were then analyzed by agarose gel 
electrophoresis for 18S and 28S rRNA to verify integrity of the RNA. RNA was 
visualized by including ethidium bromide in the gel. For microarray analysis labeled 
cRNA was synthesized from total RNA according to the standard Affymetrix protocol 
(Affymetrix, Santa Clara, CA) and hybridized to human genome U95_Av2 gene chips. 
For one lean subject, RNA material was not sufficient to be used for hybridization. 
Possible outliers were identified by principal component analysis (PCA) 155. Among the 
20 microarrays hybridized, 16 passed quality control. Nine microarrays from obese 
subjects and seven microarrays from lean subjects were used for further statistical 
analysis. The raw files containing the fluorescence probe intensity information were 
summarized into gene signals using the RMA algorithm 156. Genes differentially 
expressed between obese and lean subjects were identified using a two-tailed Student’s 
t-test. Due to the large number of tests performed, a false discovery rate (FDR) based 
multiple testing procedure was applied to control the rate of false positives 157. A FDR 
of 5% were chosen to declare a significant difference.  
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3.2.5 RNA extraction and real-time PCR  
Human fat tissue was collected and frozen at -80 °C. Tissues were disrupted using a 
Mini Beadbeater (Biospec Products, Bartlesville, OK) with 500 µl 2 mm Zirconia 
beads and further processed with the RNeasy Mini kit protocol according to the 
manufacturer (Qiagen, Valencia, CA). The RNA integrity was checked by running a 
1.5% agarose gel and the RNA concentration was determined by measuring the 
absorbance at 260 nm in a spectrophotometer. RNA quality was assessed measuring the 
A260/A280 ratio. cDNA transcription was performed using the Quantitect Reverse 
Transcription kit (Qiagen, Valencia, CA). Gene-specific primers and probe (Assay ID 
Hs00426651_m1) for real-time PCR were obtained from the Applied Biosystems assay 
on demand service and used according to manufacturer’s protocols 158. Real-time PCR 
was performed in an ABI 7300 system (Applied Biosystems). 18S was chosen as a 
reference gene for normalization. Target amplification was performed using the 
following program: 95 °C for 10 min, 95 °C for 15 s and 60 °C for 1 min for 40 cycles. 
Experiments were replicated once i.e. two measures per sample. Gene expression data 
were analyzed using the relative quantification method followed by the standard curve 
method. Differences in expression levels between study groups are described as fold-
change/difference to the reference gene. A t-test was performed to determine 
expression differences between study groups. 
 
3.2.6 Variation screening 
3.2.6.1 Paper II 
Variation screening was performed in a total of 188 subjects. For 167 subjects, DNA 
samples were obtained from the Coriell Institute for Medical Research (Caucasian 
panel and a panel of diabetic and non-diabetic subjects with family history of diabetes). 
Twenty one subjects were Swedish men from which both S.C. abdominal fat (for 
microarray profiling) and whole blood was used. Genomic DNA from these subjects 
were extracted from whole blood using MagNA Pure LC DNA Isolation Kit 1 (Roche 
Applied Science, Basel, Switzerland) and fragments targeting the complete sequence of 
AZGP1 gene were amplified using 384 Cleanup Filter plates (Millipore, Billerica, MA). 
Variation screening and analysis was performed in the 188 subjects using sequencing 
analysis based on Big Dye terminator chemistry (Applied Biosystems, ABI model 
3730, Foster City, USA). After sequencing, variation detection was performed using 
Polyphred software (University of Washington, Washington, DC). A total of 29 
variants in the AZGP1 gene were identified and 15 of them had a minor allele 
frequency of ≥ 5%. Some SNPs were completely redundant and therefore not taken into 
account. 
 
3.2.6.2 Paper IV 
Genomic DNA was extracted from peripheral blood by using a Puregene DNA 
purification kit (Gentra, USA). Screening for variation in the putative promoter region 
of the AC3 gene was performed with a protocol of direct sequencing analysis. A set of 
DNA samples extracted from 40 T2D patients and 8 non-diabetic control subjects in 
Swedish Caucasians were used. The PCR products were purified using MicroSpin HR 
columns (Amersham Biosciences, Piscataway, NJ, USA) and examined using a Big-
dye sequence kit (Applied Biosystem, ABI model 377 genetic analyzer, Perkin-Elmer, 
Foster City, USA).  
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3.2.7 Calculations and statistical analysis  
3.2.7.1 Hardy-Weinberg equilibrium 
The HWE principle states that both allele and genotype frequencies in a population 
remain constant, which mean that they are in equilibrium. This occurs from 
generation to generation if not disturbing influences are introduced. Disturbing 
influences are non-random mating, mutations, selection, limited population size, 
random genetic drift and gene flow. HWE is impossible in nature. Genetic 
equilibrium is an ideal state that provides a baseline to measure genetic change 
against. Testing deviation from HWE was performed by a χ2-test, using the observed 
genotype frequencies obtained from the association data and the expected genotype 
frequencies obtained using HWE.  
 
3.2.7.2 Homeostasis model of assessment (HOMA) 
The homeostatis model of assessment (HOMA) is a method used to quantify insulin 
resistance and β-cell function. It was first described under the name HOMA in 1985 159. 
In this thesis the HOMA was used to assess insulin resistance. Based on fasting glucose 
and insulin levels, it was calculated according to the following equation: fasting plasma 
glucose (mmol/l) x fasting plasma insulin (mU/ml)/22.5 159.  
 
3.2.7.3 Data preparation 
Normal probability plots were created and parameter distributions were transformed to 
natural logarithm as required to improve skewness and to obtain a normal distribution 
before performing statistical analysis. Homogeneity of variances was tested by 
Levene’s test, which is an inferential statistical method used to assess the equality of 
variance in different samples. Some common statistical procedures assume that 
variances of the populations from which different samples are drawn are equal. 
Levene's test assesses this assumption. It tests the null hypothesis that the population 
variances are equal. If the resulting p-value of Levene's test is less than some critical 
value (typically 0.05), the obtained differences in sample variances are unlikely to have 
occurred based on random sampling. Thus, the null hypothesis of equal variances is 
rejected and it is concluded that there is a difference between the variances in the 
population. 
 
3.2.7.4 Subgroup analysis 
For comprehensive analysis (papers I, II and IV), T2D patients were divided into 
subgroups based upon a BMI cutoff of 30 kg/m2, that is non-obese T2D patients with 
BMI <3 0 kg/m2 and obese T2D patients with BMI ≥ 30 kg/m2. Since most of T2D 
patients are obese or overweight, a limited number of T2D patients had BMI ≤ 26 
kg/m2.  
 
3.2.7.5 Allelic association 
Genetic association between groups and different SNPs was performed using an 
Armitage’s trend test 160 or χ2-test. Armitage’s trend test is often used as a genotype-
based test for case-control association studies. OR and 95% confidence intervals (CI) 
were calculated to test for relative risk for association.  
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3.2.7.6 Analysis of variance (ANOVA) 
ANOVA gives a statistical test of whether the means of several groups are all equal, 
and therefore generalizes Student's two-sample t-test to more than two groups. Test for 
differences in clinical parameters between genotype groups was performed by using 
ANOVA and covariance analysis adjusting for age. P-values less than 0.05 were 
interpreted as statistically significant.  
 
3.2.7.7 Multiple logistic regression 
Multiple logistic regression is used for prediction of the probability of occurrence of an 
event by fitting data to a logistic curve. It is a generalized linear model used for 
binomial regression. It makes use of several predictor variables that may be either 
numerical or categorical. Logistic regression is used extensively in the medical 
sciences. Multiple logistic regression analysis was used to predict the susceptibility to 
T2D between case and control subjects. Adjustments for age, sex, BMI, and blood 
pressure (where appropriate) were applied.  
 
3.2.7.8 Linkage disequilibrium and haplotype analysis 
LD is an allelic association where risk alleles of two different SNPs/markers that are 
close to each other co-segregate in one haplotype with frequencies different than 
expected. LD is the non-random association of alleles at two or more loci, not 
necessarily on the same chromosome. LD describes a situation in which some 
combinations of alleles or genetic markers occur more or less frequently in a population 
than would be expected from a random formation of haplotypes from alleles based on 
their frequencies. Non-random associations between polymorphisms at different loci 
are measured by the degree of LD. 
 
The effects of the studied SNPs were tested individually and/or as haplotypes. LD and 
haplotype frequencies were calculated using Arlequin 161 or the Haplotype program 
(EH-plus) (ftp://linkage.rockefeller.edu/software/eh). LD between different 
markers/SNPs was summarized using |D´|. Haplotypes prevalent at 5% were used for 
further haplotype analysis. In paper IV, haplotypes were analyzed as diplotypes. A 
diplotype is a pair of haplotypes.  
 
All statistical analyses were performed using Statistica version 8.0 (Statsoft Inc., Tulsa, 
OK, USA) and/or Biomedical package (BMDP) version 1.1 (BMDP Statistical 
Software Inc., Los Angeles, CA, USA) and/or Partek software version 6.4 (Partek, St 
Louis, MO) or Statistical Analysis System (SAS), version 9.1 (SAS Institute, Cary, NC, 
USA). 
 18 
4 RESULTS 
 
4.1 TYPE 2 DIABETES  
4.1.1 RPTPσ 
This genetic association study evaluated the influence of polymorphisms of the RPTPσ 
gene in development of T2D among Swedish men and women. The cohort included 
497 unrelated subjects with NGT (246 men/251 women), 262 subjects with IGT 
(107/155), and 298 patients with T2D (241/57). A total of 12 valid SNPs were 
genotyped by DASH and all of them were in HWE (P>0.05). Three SNPs were 
associated with disease, rs1143699, rs4807015, and rs1978237, see Table 2. 
 
Table 2. Allelic association of SNP rs1143699 and rs1978237 in NGT, IGT subjects and T2D 
patients 
SNP ID  Sex Allele frequencies (%) P-value OR (95% CI) 
  NGT IGT T2D T2D T2D 
rs1143699 M C84/T16 C86/T14 C89/T11 0.029 1.57 (1.05-2.36) 
 F C89/T11 C89/T11 C89/T11 NS - 
 M+F C87/T13 C88/T12 C89/T11 NS - 
rs4807015 M C51/T49 C49/T51 C47/T53 NS - 
 F C59/T41 C55/T45 C53/T47 NS - 
 M+F C56/T44 C52/T48 C49/T51 0.025 1.32 (1.03-1.68) 
rs1978237 M G71/C29 G65/C35 G79/C31 NS - 
 F G73/C27 G74/C26 G78/C22 NS - 
 M+F G72/C28 G70/C30 G80/C20 0.002 1.59 (1.18-2.13) 
P-value represents allele frequency difference between NGT vs. T2D. NS: not significant, M: male, F: 
female. 
 
SNP rs1143699 showed significant allelic association with male T2D patients when 
compared with NGT controls. Multivariate logistic regression analysis of SNP 
rs1143699 with adjustments for age, BMI, and blood pressure indicated that in men the 
C/C genotype was significantly associated with T2D when compared with C/T + T/T. 
 
A significant difference in allele frequency was found in SNP rs4807015 comparing 
male and female T2D patients with NGT controls (0.49 vs. 0.56), C being the major 
allele present at a lower frequency in T2D. Multiple logistic regression analysis showed 
that this SNP was associated with increased risk of T2D in men and women carrying 
the C/C genotype adjusted for age and blood pressure.  
 
SNP rs1978237 showed significant allelic association with male and female T2D 
patients when compared with NGT controls (0.80 vs. 0.72), where the major allele G 
was present at a higher frequency in T2D. Multiple logistic regression analysis showed 
that this SNP was associated with increased risk of T2D in men and women carrying 
the G/G genotype adjusted for age, BMI, and blood pressure.  
 
4.2 OBESITY  
4.2.1 AZGP1 
Through microarray gene expression we detected a significantly decreased expression 
of AZGP1 in S.C. abdominal fat in obese human subjects compared to lean subjects, 
Figure 3.  
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Figure 3. Box plot of AZGP1 expression signals and rs2525554 genotypes in lean and obese 
subjects. Expression signal values are normalized and log2-transformed. Lean and obese subjects appear 
in white and black circles respectively. The corresponding genotype for each subject is displayed within 
the circles. For one obese subject genotype data was not available. P=3.32 x 10-5.  
 
We further investigated the differential expression of AZGP1 in human abdominal, 
omental and thigh adipose tissue to establish the role of AZGP1 in different regions of 
fat. As shown in Figure 4, AZGP1 showed significantly decreased expression ratio in 
abdominal fat of obese subjects compared to lean. Thus, the differential expression 
between the two groups is 4.7-fold. AZGP1 also showed significant down-regulation by 
2.5-fold in omental fat in obese patients, but its expression did not differ between study 
groups in thigh fat, Figure 4. 
 
 
Figure 4. AZGP1 gene expression levels in abdominal, omental and thigh fat. Gene expression data 
of AZGP1 in obese (dark grey bars, n=6) and lean (light grey bars, n=4) subjects measured with real-time 
PCR. The levels in S.C. abdominal fat were down-regulated by 4.7-fold in obese compared to lean 
subjects, 1.9 vs. 8.9 (fold-change) respectively. In omental fat the levels were down-regulated by 2.5-fold 
in obese compared to lean subjects, 5.9 vs. 14.6 (fold-change) respectively. In S.C. thigh fat the 
expression levels did not differ between the two study groups, 3.5 vs. 5.0 (fold-change), P=0.32. 
*P≤0.01. Error bars represent SD. 
 
We also studied polymorphisms in AZGP1 in association with obesity and/or T2D in 
816 Swedish men, including 290 unrelated lean subjects with NGT, 199 obese subjects 
with NGT, 86 obese subjects with IGT and 241 subjects with T2D. A total of four valid 
SNPs in the AZGP1 gene were genotyped by DASH and TaqMan. All of them were in 
HWE (P>0.05). SNP rs2525554 was associated with obesity in Swedish men.  
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Quantitative trait analysis revealed a significant association with increased BMI, waist 
circumference (WC), waist-hip ratio (WHR) and 2h glucose. Decreased AZGP1 gene 
expression in obese subjects was related to their genotype for SNP rs2525554 as the 
risk allele T was seen more frequently among the obese compared to lean subjects, 
Figure 3. 
 
4.2.2 ADRA2A 
This study addressed the role of ADRA2A genetic variation in human T2D and/or 
obesity in a Swedish cohort including healthy controls with NGT and a BMI of ≤ 26 
kg/m2 (n=580; 394 men/186 women), IGT subjects with BMI between 21.8-44.8 kg/m2 
(n=109; 87 men/22 women), T2D patients with BMI between 18.4-46.2 kg/m2 (n=399; 
235 men/164 women) and obese subjects with NGT and BMI ≥ 30 kg/m2 (n=198 men). 
We genotyped three SNPs in the ADRA2A gene by TaqMan allelic discrimination in 
our clinical material. Genotype distributions of all studied SNPs followed HWE. Test 
for associations in all SNPs were performed. We found associations linked to two of 
the studied SNPs, rs553668 in men and rs521674 in women.  
 
SNP rs553668 in the ADRA2A gene showed significant association with obesity. The 
association was also seen when performing multiple logistic regression analysis 
adjusting for age. For a summary of association and multiple logistic regression of 
rs553668 in men, see Table 3.  
 
Table 3. SNP rs553668: Genotype distribution and association in men 
rs553668 
Comparisons Genotype distribution Armitage’s trend test Multiple logistic 
regression G/G vs. A/A 
  G/G G/A A/A OR CI 95% P OR 95% CI P 
Lean NGT vs. T2D  295/158 89/65 7/10 1.50 1.08-2.01 0.017 3.02 1.00-9.26 0.050a 
Lean NGT vs. T2D             2.29 0.35-15.06 0.389b 
Lean NGT vs. 
Obese NGT  
215/134 67/55 5/9 1.51 1.03-2.07 0.034 2.91 1.00-8.87 0.061a 
Lean NGT vs. Lean 
T2D  
295/40 89/11 7/2 1.09 0.61-1.95 0.783 1.77 0.24-12.79 0.573a 
Lean NGT vs. 
Obese T2D  
295/118 89/54 7/8 1.61 1.14-2.22 0.007 3.80 0.92-2.62 0.056a 
Obese NGT vs. 
Obese T2D  
134/57 55/26 8/4 1.11 0.70-1.74 0.675 0.77 0.20-3.05 0.712a 
Lean+Obese NGT 
vs. Lean+Obese 
T2D  
427/157 141/65 14/10 1.33 1.00-1.76 0.061 1.96 0.76-5.09 0.165a 
Adjusted by a) age and b) age and BMI 
 
As to SNP rs521674 we found association between lean NGT subjects and obese T2D 
patients.  Multiple logistic regression analysis was carried out and confirmed the 
association adjusting for age. We did not have access to obese women with NGT and 
could therefore not compare this group with lean women with NGT. We interpret the 
findings as indicating the association between SNP rs521674 and obesity in women but 
we were not able to exclude a link to T2D. Table 4 demonstrates tests for association 
and multiple logistic regressions for SNP rs521674 in women. 
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Table 4. SNP rs521674: Genotype distribution and association in women   
rs521674 
Comparisons Genotype distribution Armitage’s trend test Multiple logistic 
regression A/A vs. T/T 
  A/A A/T T/T OR CI 95% P OR 95% CI P 
Lean NGT vs. T2D  106/103 60/54 14/3 4.54 1.27-16.25 0.012 7.43 1.66-33.26 0.008a 
Lean NGT vs. T2D             2.59 0.39-16.93 0.322b 
Lean NGT vs. Lean 
T2D  
106/22 60/12 14/2 1.13 0.62-2.07 0.699 2.19 0.35-13.45 0.399a 
Lean NGT vs. 
Obese T2D  
106/81 60/42 14/1 1.94 1.00-2.25 0.050 9.42 1.02-87.33 0.048a 
Lean+Obese NGT 
vs. Lean+Obese 
T2D  
106/102 60/54 14/3 1.61 1.00-2.01 0.082 7.38 1.64-33.14 0.009a 
Adjusted by a) age b) age and BMI. 
 
4.2.3 AC3 
In this study we investigated the association of T2D with AC3 genetic variation in 
Swedish men. We carried out variation screening for the putative promoter region of 
human AC3 gene and identified a novel SNP, -17A/T. A total of 630 unrelated men 
were included in this study. They were healthy control subjects with NGT and BMI ≤ 
26 kg/m2 (n=188), T2D patients with BMI 18.4-45.6 kg/m2 (n=243) and obese subjects 
with NGT and BMI ≥ 30 kg/m2 (n=199). We genotyped 14 valid SNPs, including the 
novel polymorphism, by DASH and TaqMan allelic discrimination. All studied SNPs 
were in HWE. The identified SNP –17A/T in the promoter region of the human AC3 
gene was not associated with disease. We found that two other SNPs, rs2033655 and 
rs1968482, had significant differences of allele frequencies when comparing control 
subjects and all T2D patients. Analyses for genotype differences showed that both 
SNPs, rs2033655 and rs1968482, were associated with obese T2D. We further 
genotyped the obese subjects with NGT and found that both SNPs rs2033655 and 
rs1968482 were strongly associated with obesity. Logistic regression analyses indicated 
a significant association with genotype distribution of these two SNPs in the obese 
subjects. Similar results were obtained when age was included in the model. Results 
described above are summarized in Table 5A and B.  
 
Table 5. Association of SNPs rs2033655 (A) and rs1968482 (B) with T2D patients and obese 
subjects in comparison with control subjects 
A. SNP rs2033655  
Groups 
 
Genotypes         
 
MAF  
(%)  
Allelic association 
 
Recessive modelc 
 
 T/T T/C C/C  OR 95% CI P-value OR 95% CI P-value 
Controls                       34 96 51 C 0.55       
All T2D  31 101 98 C 0.65 1.509 1.14-2.00 0.004 1.892 1.28-2.87 0.003 
        1.837 1.13-2.98 0.014d 
 T2D (BMI ≤26 kg/m2) 11 22 17 C 0.56 0.817     0.425/0.842d 
 T2D (BMI <30 kg/m2) 21 65 56 C 0.62 1.370 1.00-1.88 0.051 1.660 1.04-2.65 0.033/0.127d 
 T2D (BMI ≥30 kg/m2) 10  36 42 C 0.68 1.775 1.22-2.59 0.003/0.202a 2.327  1.37-3.95 0.002 
        2.360 1.26-4.41 0.007d 
Obese 30  89 80 C 0.63 1.384 1.04-1.85 0.028/0.195b 1.714  1.11-2.64 0.014 
        1.744 1.13-2.69 0.012d 
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B. SNP rs1968482 
Groups 
 
Genotypes 
 
MAF  
(%) 
Allelic association 
 
Recessive modelc 
 
 
 A/A A/G G/G  OR 95% CI P-value OR 95% CI P-value 
Controls                       65 91 28 A 0.60       
All T2D  107 103 20 A 0.69 1.475 1.11-1.97 0.008 1.593 1.07-2.37 0.022/0.078d 
 T2D (BMI ≤26 kg/m2) 20 28 4 A 0.65 0.325     0.678/0.924d 
 T2D (BMI <30 kg/m2) 60  68 13 A 0.67 0.084     0.185/0.435d 
 T2D (BMI ≥30 kg/m2) 47 35 7 A 0.73 1.571 1.19-2.59 0.005/0.190a 2.049 1.23-3.43 0.006 
        2.018 1.11-3.68 0.022d 
Obese 101 77 20 A 0.71 1.586 1.18-2.14 0.003/0.622b 1.906 1.26-2.88 0.002 
        1.913 1.27-2.89 0.002d 
a) comparison analysis for T2D (BMI ≥ 30 kg/m2) vs. T2D (BMI < 30 kg/m2). b) comparison analysis for 
Obese vs. T2D (BMI ≥ 30 kg/m2). c) without adjusting for age. d) age was included in the regression 
model. MAF=Major allele frequency. 
 
Analyses of haplotypes and diplotypes were also performed. Four haplotypes were 
constructed from the two associated polymorphisms. Haplotype frequencies in controls 
were significantly different from T2D and obese subjects. Diplotype association 
analyses revealed a significant association with BMI in obese subjects, Figure 5. The 
result was the same after adjusting for age.  
 
BMI (kg/m2) in obese subjects                                               P=0.004
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Figure 5. Diplotype association with BMI in obese subjects. Data were mean values (±SE) of BMI 
according to diplotype groups. The number of individuals in each haplotype is shown in the base of each 
column. ANOVA P-value is shown. 
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5 DISCUSSION 
 
5.1 GENETIC EFFECTS OF AZGP1, ADRA2A AND AC3 IN OBESITY 
5.1.1 AZGP1  
AZGP1 is lipid mobilizing factor, which directly stimulate lipolysis in vitro through the 
cAMP pathway 162. AZGP1 causes loss of body weight in two outbred strains of mice, 
NMRI and MF-1, generally used for physiology. This phenomenon was also seen 
previously for LMF 93. AZGP1 is also expressed by human adipocytes and regulated by 
TNF-α and PPARγ, suggesting a role in inflammation and insulin sensitivity. 
Furthermore, these two factors regulate adiponectin in mouse, suggesting a functional 
relationship between adiponectin and AZGP1 96. In concert with our findings, recent 
studies have investigated the expression of AZGP1 in S.C. abdominal and omental fat 
of obese and lean subjects and found that AZGP1 was down-regulated in obese subjects 
100 163-164. We found that in lean subjects, AZGP1 expression in S.C. thigh fat was lower 
than in the other locations, and with no different expression as compared with obese 
subjects, suggesting that S.C. thigh fat plays a subordinate metabolic role. It is possible 
that a decrease of both expression and activity of AZGP1 in white and brown adipose 
tissue accounts for reduced rates of lipolysis and UCP function 92-93 95.  AZGP1 is thus 
involved in lipid metabolism and can be seen as a candidate gene in obesity regulation 
89 99-100 163-164. 
 
5.1.2 ADRA2A 
SNP rs553668 has been reported to be associated with risk of obesity in Caucasians and 
African Americans 114-116, hypertension in African Americans 119 and with endurance in 
athletes of Caucasian origin 165. This polymorphism has also been associated with 
childhood ADHD, hypertension and platelet aggregation 121 166-167. Our study confirms 
the association with SNP rs553668 and obesity in Swedish men.  
 
Recently, it was reported that SNP rs553668 is associated with reduced insulin 
secretion and increased risk of T2D 118 in a population from Finland and Southern 
Sweden. The association was verified on functional level in human pancreatic islets. 
Risk allele carriers showed over-expression of ADRA2A in islets, decreased insulin 
secretion and reduced number of docked insulin granules in vitro. The defects were 
corrected by ADRA2A-antagonism 118. Taking into consideration these findings and 
our present study, we propose that ADRA2A is a common component in obesity and 
T2D, which may allow future specific therapy for individual patients and personalized 
medicine.  
 
Variants in the β3- and β2-adenergic receptors have previously been associated with 
obesity and diabetes in several studies 168-171. There is a major interest in the receptor 
variants and their association with altered function and etiology of disease. Many 
candidate genes have been proposed for obesity and yielded conflicting associations 
with obesity-related traits 60. The reason for this might be sample size, different selected 
populations, gene-gene and gene-environment interactions or lack of reproducibility.  
 
5.1.3 AC3 
It has been demonstrated that AC/cAMP/protein kinase A axis is involved in regulation 
of both insulin release and lipolysis. Important incretin hormones such as glucagon-like 
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peptide (GLP-1), gastric inhibitory polypeptide (GIP) and β-adrenergic agonists are 
known to stimulate insulin release by increasing synthesis of cAMP 130 172-174. In 
humans, the most important regulators of lipolysis are catecholamines, which stimulate 
mobilization of fat through β-adrenergic receptors and generation of cAMP, whereas 
α2-adrenergic receptors suppress cAMP generation and lipolysis. cAMP influences may 
be important in regulating pancreatic islet β-cell function, differentiation, growth and 
survival 175. ACs 1, 3 and 8, are most abundantly expressed in the brain and islets, 
where the cells need an elevated cAMP level to respond to multiple stimuli 103 176-177. 
AC3 may play an interactive role with GLP-1, GIP and adrenergic receptors in control 
of insulin release and lipolysis. Therefore, a comprehensive analysis of AC3 in 
regulation of signaling by GLP-1, GIP and adrenergic receptors is necessary in order to 
understand the cellular mechanisms behind the postulated influence of AC3 genetic 
variation on BMI and other related metabolic features in T2D and obesity.  
 
Our results suggest that AC3, which is expressed in adipose tissue and the 
hypothalamus, may play an important role in the regulation of body weight. Another 
group has studied this hypothesis by disrupting the AC3 gene and monitoring the 
weight of AC3-/- mice over an extended period of time to see if they develop obesity. 
The mice phenotype is consistent with the hypothesis that AC3 generates a cAMP 
signal in the primary cilia of the hypothalamus that is important for regulation of 
weight and leptin sensitivity 178. The study by Wang et al. report that mice lacking AC3 
exhibit obesity which is caused by low locomotor activity, hyperphagia and leptin 
resistance. The phenotype of the AC3-/- mouse is consistent with our data implicating a 
role of AC3 polymorphisms in human obesity.  
 
5.2 GENETIC INFLUENCE OF RPTPΣ IN TYPE 2 DIABETES 
LAR is a member of the same PTP family as RPTPσ and has a role in negative 
modulation of insulin receptor signaling 179. Increased activity of LAR or related PTPs 
in insulin target tissues could contribute to development of insulin resistance 180. The 
fact that RPTPσ shows similarity to LAR, 85% at amino acid level, and is expressed to 
a higher level than LAR in insulin-sensitive tissues, makes this protein a possible 
candidate for regulating insulin signaling and for playing a role in glucose homeostasis 
181. To our knowledge, the present study is the first genetic investigation of RPTPσ in 
T2D. However, there is a genetic association study of an SNP in the promoter region of 
LAR in two non-diabetic populations in Italy, showing association with diabetes-
related characteristics 182. Thus, LAR and RPTPσ seem to be important genes in the 
development of T2D.  
 
5.3 CANDIDATE GENE APPROACH 
No results from candidate gene studies have reached genome-wide significance and 
meta-analysis did not improve the outcome 35. Candidate gene association studies have 
not produced univocal results but the results that exist are strong enough if associations 
found are replicated, suggesting that many of these variants have a modest effect on 
obesity and T2D 35. 
 
One difficulty with this approach is that many studies are small and therefore 
underpowered. The smaller the effect of a genetic variant and the lower the minor allele 
frequency, the larger sample size is required to identify an association with sufficient 
power. 
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The candidate gene approach will in the future continue to contribute to our 
understanding of obesity and T2D susceptibility, because it can perform more detailed 
analyses of biological relevant genes and their interaction with other genes and the 
environment. It requires large-scale cohorts and meta-analyses to confirm detected 
gene-disease associations. Associations should be looked at in populations with 
different environments and ethnic backgrounds. Negative association in one 
environment/ethnicity does not exclude positive association in another. 
 
The individual effect of each genetic variant is often small and explains only a portion 
of the total heritability of the disease 183. For several genes associated with complex 
diseases results have not been replicated and this raises concerns to design and 
interpretation of studies. Any association testing needs to include statistical power 
estimates, sample size and case-control stratification 184-190. Careful study design can 
reduce study bias and false-positive results can be minimized. By controlling the 
probability of type I error there is also a possibility of ignoring important biological 
findings 191. Replication should be carried out in a larger sample set from an 
independent study population with the same genetic background, phenotype and SNPs. 
Replication can be performed in a population of different genetic background to 
strengthen the evidence for true association. Although, if no association is seen it 
should not be taken as false positive evidence 192. 
 
Even though GWA studies have brought a lot of new information, large-scale candidate 
gene studies will still be essential in the near future. The costs of SNP chips have 
decreased, although not everyone will be able to afford to genotype their samples by 
this technique. The candidate gene approach can evaluate specific genes in greater 
depth by the selection of tagSNPs or by sequencing a gene of interest. SNP chips do not 
capture all common genetic variation of the genome yet and they only cover a part of 
all rare variants. It might be rare rather than common variants, or a combination of 
both, that accounts for the variability of complex traits 193. 
 
5.4 GENOME-WIDE ASSOCIATION STUDIES 
After the initial GWAS and meta-analysis of most of them, there have been 
speculations about the clinical use and impact of the results. Many of the identified 
T2D loci seem to be related to β-cell function. These findings are partially related to the 
selection process of cases and controls in the GWAS. Two of the studies 71 75 selected 
lean cases to control for obesity. By minimizing the influence of obesity and therefore 
also insulin resistance, the chance of identifying insulin secretion genes increased. 
Another study that did not control for obesity found an association with FTO. When 
BMI was taken into account the association disappeared, which suggests that the 
association of FTO with T2D is mediated by obesity 53. However, it has also been 
found that FTO variants are associated with insulin resistance in obese children and 
adolescents independent of BMI 194. 
 
The GWA studies are today using markers with a minor allele frequency over 5%, 
which fails to detect rare variants of large effect 35. It is important to remember that the 
contribution of genetic variants to obesity is estimated to be small. This could be due to 
the current study designs, which include specifically selected obese subjects where the 
main phenotype studied is BMI. There are other obesity-related phenotypes that could 
give important information. Candidate gene studies are able to focus on specific 
subgroup populations such as different ethnicities or children, investigate more detailed 
traits and study interactions with the environment. 
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The large data sets generated by GWAS are a challenge when it comes to analysis and 
interpretation. In the future GWAS also need to be extended to other populations to 
shed light to shared and population specific variants. The majority of the GWAS so far 
have been performed in North America or Western European individuals 35. The 
majority of SNPs in commercially available arrays does not affect protein structure and 
seems unlikely to affect gene expression. This limits the discovery to finding 
chromosomal locations instead of genetic variants 195. Fine mapping and sequencing is 
required for identifying functional variants 191 195-197. 
 
We will not be able to elucidate the genetic architecture of common obesity and T2D 
by GWAS alone. We need alternative study designs and additional phenotype data to 
find new genes 35. The GWA approach needs to be experienced further and some issues 
remains to be considered. Study design, number and selection of SNPs, population 
selection, statistical analyses are potential hurdles 184 198-200. 
 
5.5 INTRONIC POLYMORPHISMS AND THEIR BIOLOGICAL 
RELEVANCE 
All but one of the presently associated variants with T2D is located in non-coding 
regions. Whether these variants have effects on regulatory elements and gene 
expression is still unclear. Many of the identified genes are located near genes that 
could affect β-cell function. This can be a reflection of the study design of GWA 
studies, which focus on individuals with established T2D and thus β-cell dysfunction. It 
is of importance to study subjects with insulin resistance as the primary phenotype. 
Interestingly, many genes are widely expressed throughout the body. They could 
therefore have roles in tissues that are not investigated in clinical studies 77.  
 
The majority of the associated variants in this thesis are located in introns. Two of the 
associated variants in the RPTPσ gene are located in intron 13 and 34, the associated 
variant in the AZGP1 gene is located in intron 2 and the two associated variants in the 
AC3 gene are located in introns 1 and 2. In other genes, intronic SNPs have been 
suggested to contribute to gene expression, and therefore, this is a possible explanation 
for the role of these SNPs as well 59 201-202. Susceptibility is often a result of the 
combined action of many different variants in a gene, one example being calpain-10 in 
T2D 203. Thus, the susceptibility of a single gene is small. It is the contribution of 
several genes combined with environmental components that will give rise to disease 
188 . These considerations need to be emphasized when interpreting association data of 
genetic association studies.  
 
One of the associated variants in the ADRA2A gene is located in the 3´-region. Genetic 
variations in the 3´-region can be important in regulation of message stability. 
Alteration in this region of the ADRA2A gene can affect gene expression by causing an 
increased stability of the mRNA 204. The other associated SNP in the ADRA2A gene is 
situated in the 5´-region. Due to its location, this polymorphism has previously been 
described and used as a genetic marker 205-206. Genetic variants found in the 5´-flanking 
region could be involved in transcription binding sites in the promoter region and 
influence gene expression. There is little information on in vivo effects of studied SNPs 
in the ADRA2A gene. The variants found are mainly non-coding and there is limited 
knowledge on their functional significance.  
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5.6 GENDER SPECIFIC ASSOCIATIONS 
SNP rs1143699 in the RPTPσ gene was found to be associated with T2D in men but 
not in women, suggesting that gender differences may be an important factor in the 
genetic influence of RPTPσ in T2D. Our group and others have previously shown that 
there are sex differences in genetic association with T2D. Polymorphisms in the 
insulin-degrading enzyme (IDE) gene are associated with increased BMI and insulin 
resistance in men but not in women 207. Also, a polymorphism in neuropeptide Y 
(NPY), a gene involved in satiety and body weight, is related to IGT and T2D in men 
208. Thus, sex specificity could be an important confounding factor in analyzing 
genetics of T2D and related disorders 136 207-212 and at least partly explain the higher 
prevalence of T2D in men vs. women in ages 35-65 years 6 136. We also detected gender 
specific associations in the ADRA2A gene, but because of the limited size of our obese 
female samples in this study the results should be evaluated further and replicated in 
larger populations. Hence, gender seems to be an important factor to take into account 
when analyzing genetics of obesity and related disorders.  
 
5.7 STOCKHOLM DIABETES PREVENTION PROGRAM 
We did not detect any association between genotype groups and clinical phenotypes for 
the SNPs in the RPTPσ, ADRA2A or the AC3 gene. This is most probably because our 
male patient group contains clinical data at baseline also for patients who were 
diagnosed with T2D during the 8-10 years between baseline and follow-up studies. 
This subgroup of T2D men did not have diabetes at baseline, which explains the low 
fasting plasma glucose in the diabetes group (6.6 mmol/l). However, we chose not to 
include follow-up data of these patients, since anti-diabetic drugs and lifestyle changes 
would then be affecting the quantitative traits of the patients. The same analysis 
approach was applied to all genetic association studies in this thesis.  
 
5.8 GENE-GENE AND GENE-ENVIRONMENT INTERACTIONS 
There is an increased awareness of the role of gene-gene interaction, or epistasis, in 
complex diseases. Epistasis is a common component of polygenic disorders and is 
thought to be more important than the independent effect of a susceptibility gene 213. 
Physiological events are generally not regulated by a single gene. Linkage studies 
demonstrate chromosome 7q22.1- 7q35 to be a region of interest for association to 
obesity 214. In addition to AZGP1, this region contains the leptin gene, encoding another 
body weight regulating hormone. Thus, it is of interest to study this gene region 
regarding interactions of AZGP1 with leptin or other genes. Minor gene interactions 
might be essential for understanding obesity and T2D 94. Studies have also found a 
positive correlation of AZGP1 expression to serum adiponectin and a negative 
correlation with serum leptin, supporting previous findings that AZGP1 may affect the 
production of other adipokines 96 164.  
 
It remains to be investigated how the ADRA2A association is regulated on a molecular 
basis in lipid and glucose metabolism. It is also of interest to study the effects of 
ADRA2A variants on response to administration of α2-adrenoreceptor agonists and 
antagonists. Not only single but interactive effects of adrenergic receptor 
polymorphisms seem to contribute to obesity-related phenotypes such as 
hyperinsulinemia, insulin resistance and increased systolic blood pressure 215-216. It is 
also important to study other components of the adrenergic receptor pathways in 
relation to the pathogenesis of T2D and obesity. The interest for gene-environment 
interactions is also growing. Non-genetic factors may play a major role in common 
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disorders. The prevalence of late-onset diseases have increased during the past decades 
and this increase is likely caused by non-genetic factors that trigger the disease in 
individuals that are genetically susceptible. Environmental factors have changed more 
recently than common disease alleles in the population 62. Thus, other polymorphisms 
and environmental factors will give a better insight into the susceptibility, progression 
and treatment of obesity, T2D and related disorders.  
 
5.9 GENETIC RESEARCH OF COMPLEX DISEASES 
The advances in understanding the genome will be integrated into genetic studies. Once 
a genetic variant is identified further studies of epidemiological, genetic and 
physiological ground is needed. To determine which variants within a haplotype that 
are functionally related to disease, it is important to perform haplotype analyses on 
populations of different ethnicities by fine mapping the region of interest using 
sequencing in a large number of individuals. Expression studies will identify if the 
variants affect mRNA and protein levels. Since obesity and T2D are heterogeneous 
disorders, refining the phenotypic outcome can give more detailed information of the 
mechanisms that drive an association. It would be desirable to use more detailed 
additional phenotypic information such as diet, energy expenditure, physical activity, 
food intake, body fat percentage or fat distribution. This is essential if the genetic 
studies are going to provide information. Experiments at cellular level or in animal 
models will give us better understanding of molecular and physiological mechanisms 
and pathways that underlie an observed association. The genetic research of the last ten 
years have led to the identification of ~27 confirmed and potential T2D susceptibility 
genes 47.  
 
Rare SNPs with a minor allele frequency of less than 5% have shown strong effects in 
common complex diseases such as obesity 217, T1D 218 and infection 219. This suggests 
that both common and rare variants contribute to common disease. Copy number 
variants (CNVs) have been estimated to be causing 18% of the heritable variance in 
gene expression 220. CNVs include copy number gains (duplications or insertions), 
losses (deletions) and rearrangements. Obesity associated SNPs in the neural growth 
regulator (NEGR1) gene have shown to be in strong LD with a nearby CNV 221.  
 
A growing field is the regulatory role of microRNAs (miRNAs) 222. They are small 22-
bp non-coding RNAs that bind to target mRNA and modify their expression. One 
miRNA can regulate many targets and recently specific miRNAs have been found in 
the regulation of glucose and lipid metabolism 223-228. It is of interest to study the 
contribution of genetic variance in miRNA coding and target sequences to T2D 
pathogenesis.  
 
Epigenetics is the study of heritable changes in the genome that are not due to changes 
in the DNA sequence. The epigenetic changes are DNA methylation, histone 
methylation and chromatin modification. Imprinting is suggested to be linked to 
common polygenic obesity 229-230. 
 
Other findings that seem to be very important to the concept of obesity and diabetes 
include the ”microbiome”, which includes hundreds of species of microbes. Germ-free 
mice suggest that the microbiome is important for the energy balance 231. Furthermore, 
the brain has a major role in weight regulation and fat metabolism 232. A new concept, 
named nutri-genomics, investigates food chemicals that may alter expression of genes 
that contribute to disease 233. 
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A lot more work is needed including larger-scale studies, studies using novel 
phenotypes, deep resequencing of the genome, studies looking at the role of CNV and 
epigenetics. The long-term goal is to identify causal variants and their biological 
function in obesity and T2D. Finally, the translation of all new genetic insights into 
clinical practice continues to be the overall goal and personalized treatment will be the 
next to conquer. 
 
The genetic basis for obesity, T2D and other common diseases is complex. The 
susceptibility genes will be many and vary between families and ethnic groups. Will 
there be a common form of T2D that accounts for the majority of affected persons? The 
next 10 years will tell. When the important genes involved have been identified, the 
focus will be on developing therapies and to perform genetic testing on persons with 
disease and tailor the most effective treatment. Relatives can also undergo testing to 
determine their genetic predisposition and if they are at risk, treatment plans can be 
used for prevention 234. It has been shown that patients with the KCJN11 mutation 
respond better to sulfonylureas than insulin 235 and that carriers with the TCF7L2 risk 
variant respond poorly to sulfonylureas 236. Novel obesity and T2D genes will be 
potential pharmaceutical targets and the near future will identify more susceptibility 
genes for both disorders. Common traits are a large public health problem. The 
discovery of genetic profiles in individuals can be used to predict disease risk, 
prevention or treatment. This is one step towards personalized medicine. 
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6 CONCLUSIONS 
 
Paper I – The study provides evidence that three polymorphisms in the RPTPσ gene are 
associated with the development of T2D in Swedish Caucasians, which suggests that 
the RPTPσ gene may be important for the development of T2D in humans.  
 
Paper II – The study confirms that AZGP1 expression is down-regulated in obese 
compared to lean subjects. We provide additional verification for the role of AZGP1 in 
obesity by showing that the decreased expression is evident in S.C. abdominal and 
omental fat but not in S.C. thigh fat. SNP rs2525554 in the AZGP1 gene is associated 
with abdominal obesity in Swedish men. Thus, AZGP1 may play an important role in 
the pathogenesis of obesity.  
 
Paper III – The study suggests that ADRA2A polymorphisms are associated with 
obesity and may also relate to T2D in Swedish Caucasians. Further investigation needs 
to be performed in other populations and functional effects of genetic variation should 
be analyzed. 
 
Paper IV – The study provides the first evidence that AC3 gene polymorphisms are 
associated with obesity in Swedish men with and without T2D. AC3 seems to play an 
important role in the regulation of body weight. 
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